Art. -Nr.: HY-B0257

Levonorgestrel

(Synonyms: D-Norgestrel)

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

Levonorgestrel is an orally active inhibitor of progesterone (HY-N0437). Levonorgestrel has anticancer activity and can induce Apoptosis. Levonorgestrel can be used as a contraceptive and in combination with other medications. Levonorgestrel can be used in the study of osteoporosis and uterine leiomyoma.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.98%
CAS. Nr.: 797-63-7
Formel: C₂₁H₂₈O₂
Molecular Weight:312.45

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Levonorgestrel Chemical Structure

CAS. Nr.: 797-63-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Caspase Isoform-spezifische Produkte anzeigen :

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen :

In Vitro

Levonorgestrel (5-25 mg/mL; 72 h) inhibits cell proliferation and promotes apoptosis in uterine leiomyoma cells in a concentration-dependent manner^[1].
Levonorgestrel (0.1-100 μM; 4 h) doesn’t affect progesterone production at low doses (0-10 μM), but can inhibit progesterone production at high doses (100 μM) in luteal cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

Uterine leiomyoma cells
Concentration:

5 mg/mL; 10mg/mL; 20 mg/mL
Incubation Time:
Result:

Inhibited Bcl-2 and survivin expression at high concentrations (10 mg/mL and 20 mg/mL).
Significantly increased the phosphorylation of P38 phosphorylation and increased Caspase-3 expression at high concentrations (10 mg/mL and 20 mg/mL).

In Vivo

Levonorgestrel (0.005-0.15 mg/kg; Once every two days for three weeks) can inhibit bone resorption, decrease bone turnover, and increase bone mineral content in Sprague-Dawley rats^[3].
Levonorgestrel (1 mg/kg; Intragastric administration; Once daily for three days) provides effective contraception for Apodemus agrarius mice in combination with quinestrol (HY-B1012)^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Apodemus agrarius model^[4]
Dosage:

1 mg/kg
Administration:

Intragastric administration (i.g.), Once daily for three days
Result:

Damaged the sperm ducts, reduced sperm production in combination with quinestrol.
Reduced population density in the field in combination with quinestrol.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 797-63-7
Appearance Solid
Molecular Weight 312.45
Formel C₂₁H₂₈O₂
Color White to off-white
SMILES

O=C1CC[C@]2([H])[C@@]3([H])CC[C@]4(CC)[C@@](C#C)(O)CC[C@@]4([H])[C@]3([H])CCC2=C1
Synonyms

D-Norgestrel
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (2)

All

Sort by:

Journal Impact Factor

J Control Release

Injectable self-expanding short-fiber scaffold reduces endometrial hyperplasia. [Abstract]

2025 Aug 26:387:114172. PMID: 40876546
Preprints

2024 Jan 29.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 43.75 mg/mL (140.02 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.2005 mL

16.0026 mL

32.0051 mL

5 mM

0.6401 mL

3.2005 mL

6.4010 mL

10 mM

0.3201 mL

1.6003 mL

3.2005 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (8.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Xu Qing, et al. Levonorgestrel inhibits proliferation and induces apoptosis in uterine leiomyoma cells. Contraception vol. 82,3 (2010): 301-8. [Content Brief]

[2]. Tellería C M, et al. Levonorgestrel inhibits luteinizing hormone-stimulated progesterone production in rat luteal cells. The Journal of steroid biochemistry and molecular biology vol. 50,3-4 (1994): 161-6. [Content Brief]

[3]. Liao Er-yuan, et al. Effects of different nylestriol/levonorgestrel dosages on bone metabolism in female Sprague-Dawley rats with retinoic acid-induced osteoporosis. Endocrine research vol. 29,1 (2003): 23-42. [Content Brief]

[4]. Chen Xiaoning, et al. Anti-fertility effect of levonorgestrel and/or quinestrol on striped field mouse (Apodemus agrarius): evidence from both laboratory and field experiments. Integrative zoology vol. 17,6 (2022): 1041-1052. [Content Brief]

[5]. Meng C-X, et al. Effects of oral and vaginal administration of levonorgestrel emergency contraception on markers of endometrial receptivity. Human reproduction (Oxford, England) vol. 25,4 (2010): 874-83. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.2005 mL	16.0026 mL	32.0051 mL	80.0128 mL
	5 mM	0.6401 mL	3.2005 mL	6.4010 mL	16.0026 mL
	10 mM	0.3201 mL	1.6003 mL	3.2005 mL	8.0013 mL
	15 mM	0.2134 mL	1.0668 mL	2.1337 mL	5.3342 mL
	20 mM	0.1600 mL	0.8001 mL	1.6003 mL	4.0006 mL
	25 mM	0.1280 mL	0.6401 mL	1.2802 mL	3.2005 mL
	30 mM	0.1067 mL	0.5334 mL	1.0668 mL	2.6671 mL
	40 mM	0.0800 mL	0.4001 mL	0.8001 mL	2.0003 mL
	50 mM	0.0640 mL	0.3201 mL	0.6401 mL	1.6003 mL
	60 mM	0.0533 mL	0.2667 mL	0.5334 mL	1.3335 mL
	80 mM	0.0400 mL	0.2000 mL	0.4001 mL	1.0002 mL
	100 mM	0.0320 mL	0.1600 mL	0.3201 mL	0.8001 mL

Keywords

Levonorgestrel

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Levonorgestrel

Anti-Infection Compound Library

Apoptosis Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Lipid Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Blood Cancer Compound Library

Mitochondria-Targeted Compound Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product-like Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Alkyne Compound Library

Classic FDA-Approved Drug Library

Publications Citing Use of MedChemExpress (MCE) Levonorgestrel

Alle Caspase Isoform-spezifische Produkte anzeigen

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Levonorgestrel Related Classifications

HY-B0257 Related Classifications